Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

Mistry, P. K.; Balwani, M.; Baris, H. N.; Turkia, H. B.; Burrow, T. A.; Charrow, J.; Cox, G. F.; Danda, S.; Dragosky, M.; Drelichman, G.; El-Beshlawy, A.; Fraga, C.; Freisens, S.; Gaemers, S.; Hadjiev, E.; Kishnani, P. S.; Lukina, E.; Maison-Blanche, P.; Martins, A. M.; Pastores, G.; Petakov, M.; Peterschmitt, M. J.; Rosenbaum, H.; Rosenbloom, B.; Underhill, L. H.; Cox, T. M.

Blood Cells Mol Dis. 2018 Apr 24; 71:71-74

Read More on PubMed